Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585) : an interim analysis of the multicentre, double-blind, randomised phase 3 study

Copyright © 2024 Elsevier Ltd. All rights reserved..

BACKGROUND: The benefit of combination neoadjuvant and adjuvant chemotherapy and immune checkpoint inhibition in patients with locally advanced, resectable gastric or gastro-oesophageal adenocarcinoma is unknown. We assess the antitumor activity of neoadjuvant and adjuvant pembrolizumab plus chemotherapy in patients with locally advanced resectable gastric or gastro-oesophageal adenocarcinoma.

METHODS: The KEYNOTE-585 study is a multicentre, randomised, placebo-controlled, double-blind, phase 3 study done at 143 medical centres in 24 countries. Eligible patients were aged 18 years or older with untreated, locally advanced, resectable gastric or gastro-oesophageal adenocarcinoma, and an Eastern Cooperative Oncology Group performance status 0-1. Patients were randomly assigned (1:1) by an interactive voice response system and integrated web response system to neoadjuvant pembrolizumab 200 mg intravenously or placebo (saline) plus cisplatin-based doublet chemotherapy (main cohort) every 3 weeks for 3 cycles, followed by surgery, adjuvant pembrolizumab or placebo plus chemotherapy for 3 cycles, then adjuvant pembrolizumab or placebo for 11 cycles. A small cohort was also randomly assigned (1:1) to pembrolizumab or placebo plus fluorouracil, docetaxel, and oxaliplatin (FLOT)-based chemotherapy (FLOT cohort) every 2 weeks for four cycles, followed by surgery, adjuvant pembrolizumab, or placebo plus FLOT for four cycles, then adjuvant pembrolizumab or placebo for 11 cycles. Patients were stratified by geographic region, tumour stage, and chemotherapy backbone. Primary endpoints were pathological complete response (reviewed centrally), event-free survival (reviewed by the investigator), and overall survival in the intention-to-treat population, and safety assessed in all patients who received at least one dose of study treatment. The study is registered at ClinicalTrials.gov, NCT03221426, and is closed to accrual.

FINDINGS: Between Oct 9, 2017, and Jan 25, 2021, of 1254 patients screened, 804 were randomly assigned to the main cohort, of whom 402 were assigned to the pembrolizumab plus cisplatin-based chemotherapy group and 402 to the placebo plus cisplatin-based chemotherapy group, and 203 to the FLOT cohort, of whom 100 were assigned to the pembrolizumab plus FLOT group and 103 to placebo plus FLOT group. In the main cohort of 804 participants, 575 (72%) were male and 229 (28%) were female. In the main cohort, after median follow-up of 47·7 months (IQR 38·0-54·8), pembrolizumab was superior to placebo for pathological complete response (52 [12·9%; 95% CI 9·8-16·6] of 402 vs eight [2·0%; 0·9-3·9] of 402; difference 10·9%, 95% CI 7·5 to 14·8; p<0·00001). Median event-free survival was longer with pembrolizumab versus placebo (44·4 months, 95% CI 33·0 to not reached vs 25·3 months, 20·6 to 33·9; hazard ratio [HR] 0·81, 95% CI 0·67 to 0·99; p=0·0198) but did not meet the threshold for statistical significance (p=0·0178). Median overall survival was 60·7 months (95% CI 51·5 to not reached) in the pembrolizumab group versus 58·0 months (41·5 to not reached) in the placebo group (HR 0·90, 95% CI 0·73 to 1·12; p=0·174). Grade 3 or worse adverse events of any cause occurred in 312 (78%) of 399 patients in the pembrolizumab group and 297 (74%) of 400 patients in the placebo group; the most common were nausea (240 [60%] vs 247 [62%]), anaemia (168 [42%] vs 158 [40%]), and decreased appetite (163 [41%] vs 172 [43%]). Treatment-related serious adverse events were reported in 102 (26%) and 97 (24%) patients. Treatment-related adverse events that led to death occurred in four (1%) patients in the pembrolizumab group (interstitial ischaemia, pneumonia, decreased appetite, and acute kidney injury [n=1 each]) and two (<1%) patients in the placebo group (neutropenic sepsis and neutropenic colitis [n=1 each]).

INTERPRETATION: Although neoadjuvant and adjuvant pembrolizumab versus placebo improved the pathological complete response, it did not translate to significant improvement in event-free survival in patients with untreated, locally advanced resectable gastric or gastro-oesophageal cancer.

FUNDING: Merck Sharp & Dohme.

Medienart:	E-Artikel

Erscheinungsjahr:	2024
Erschienen:	2024

Enthalten in:	Zur Gesamtaufnahme - volume:25
Enthalten in:	The Lancet. Oncology - 25(2024), 2 vom: 01. Feb., Seite 212-224

Sprache:	Englisch

Beteiligte Personen:

Shitara, Kohei [VerfasserIn] Rha, Sun Young [VerfasserIn] Wyrwicz, Lucjan S [VerfasserIn] Oshima, Takashi [VerfasserIn] Karaseva, Nina [VerfasserIn] Osipov, Mikhail [VerfasserIn] Yasui, Hisateru [VerfasserIn] Yabusaki, Hiroshi [VerfasserIn] Afanasyev, Sergey [VerfasserIn] Park, Young-Kyu [VerfasserIn] Al-Batran, Salah-Eddin [VerfasserIn] Yoshikawa, Takaki [VerfasserIn] Yanez, Patricio [VerfasserIn] Dib Bartolomeo, Maria [VerfasserIn] Lonardi, Sara [VerfasserIn] Tabernero, Josep [VerfasserIn] Van Cutsem, Eric [VerfasserIn] Janjigian, Yelena Y [VerfasserIn] Oh, Do-Youn [VerfasserIn] Xu, Jianming [VerfasserIn] Fang, Xiao [VerfasserIn] Shih, Chie-Schin [VerfasserIn] Bhagia, Pooja [VerfasserIn] Bang, Yung-Jue [VerfasserIn] KEYNOTE-585 investigators [VerfasserIn]

Links:	Volltext

Themen:	Antibodies, Monoclonal, Humanized Cisplatin Clinical Trial, Phase III DPT0O3T46P Journal Article Multicenter Study Pembrolizumab Q20Q21Q62J Randomized Controlled Trial

Anmerkungen:	Date Completed 05.02.2024 Date Revised 05.02.2024 published: Print-Electronic ClinicalTrials.gov: NCT03221426 Citation Status MEDLINE

doi:	10.1016/S1470-2045(23)00541-7

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	NLM366256130